The US FDA approved BridgeBio’s drug for a rare and deadly heart disease, transthyretin amyloid cardiomyopathy, making it the first new treatment in a market dominated by Pfizer. Transthyretin amyloid cardiomyopathy is a disease in which defective transthyretin proteins accumulate in the heart and can lead to organ failure.